Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
| Status: | Terminated |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2005 |
| End Date: | November 2007 |
In the present application, we propose to refine and extend current insight into AAF
mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE
genotype, and their interaction in secondary AF prevention. We have 3 specific aims:
1. To confirm that RAAS inhibition therapy reduces the incidence of AF recurrence.
2. To test the hypothesis that the incidence of AF recurrence in the absence of RAAS
inhibition therapy is higher among patients with the D allele.
3. To explore the hypothesis that RAAS inhibition therapy is more effective for preventing
AF recurrence in patients with the DD genotype than in those with DI or II genotypes.
mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE
genotype, and their interaction in secondary AF prevention. We have 3 specific aims:
1. To confirm that RAAS inhibition therapy reduces the incidence of AF recurrence.
2. To test the hypothesis that the incidence of AF recurrence in the absence of RAAS
inhibition therapy is higher among patients with the D allele.
3. To explore the hypothesis that RAAS inhibition therapy is more effective for preventing
AF recurrence in patients with the DD genotype than in those with DI or II genotypes.
Inclusion Criteria:
- Subjects must be in atrial fibrillation confirmed by 12 lead EKG.
- blood pressure > 90 mmHg
- Patient without cardiopulmonary symptoms
- 18+ years of age
Exclusion Criteria:
- Contraindiction to warfarin
- Recent (within 6 months) MI or cardiac revascularization
- Recent (within 6 months) CVA or TIA
- NYHA Class IV CHF
- Active thyroid disease
- Major hepatic dysfunction
- Renal dysfunction (>2 mg/dL)
- Hyperkalemia (>4.6 mEq/L)
- Hyponatremia (<130 mEq/L)
- Currently taking a Vaughn-Williams Type I or III antiarrhythmic drug
- History of ARB intolerance
- Contraindication to ARB therapy
- Pregnancy
- Female of childbearing age
- Age < 18 years of age
- Inability to give informed consent
- Other medical conditions calling 1 year survival into question
We found this trial at
1
site
Click here to add this to my saved trials
